We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sales of Aduhelm and any other antiamyloid antibodies approved in the future will hinge on the National Coverage Determination for the new class of drugs. Read More
A federal judge has ruled that Eli Lilly must pay 2 percent of its billions in insulin sales to business development service firm Research Corp. Technologies (RTC) because the drugmaker had signed a royalty agreement in 1992 allowing Lilly to use a specific strain of yeast to make the medicines. Read More
The agreement will make Alunbrig available to Point32Health’s more than 2 million members “with Takeda standing behind the medicine with a unique outcomes-based structure,” the companies said. Read More
Biogen has so far netted just $300,000 from the sale of Aduhelm, its controversial antiamyloid antibody, a fraction of what the company anticipated for its recently approved Alzheimer’s treatment. Read More
Since the pandemic began, the Gates Foundation has previously spent $1.9 billion to support research and development and manufacturing efforts for COVID-19 vaccines, drugs and tests. Read More
Takeda Pharmaceutical has signed a risk-sharing agreement with Point32Health, the second-largest health plan in New England, that has Takeda returning a portion of the cost of its lung cancer drug Alunbrig in circumstances when it doesn’t work. Read More
Chinese biopharmaceutical company BeiGene is refusing to dissolve its Abraxane cancer drug deal with Bristol Myers Squibb (BMS), saying that the U.S. company’s proposed pull-out deal is just an attempt to stem potential arbitration costs, according to a new filing with the Securities and Exchange Commission (SEC). Read More
Sanofi said that supply for all four formulations of Kevzara ― 150 mg, 200 mg, prefilled syringe and auto-injector ― are expected to be limited until early 2022 based on current projections. Read More
Pacira BioSciences will pay close to $427.5 million to buy pain management company Flexion Therapeutics, maker of Zilretta, a nonopioid injection approved in 2017 for chronic osteoarthritis. Read More